Showing 421-430 of 7650 results for "".
How Health Care Worker Dissatisfaction is Fueling a New Trend in Health Care
https://practicaldermatology.com/topics/practice-management/how-health-care-worker-dissatisfaction-is-fueling-a-new-trend-in-health-care/23837/Despite strain, many health care workers are finding new opportunities.Unplugged: Cutting-Edge Aesthetic Medicine
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/unplugged-cutting-edge-aesthetic-medicine/20142/Jeanine Downie, MD shares pearls from her presentation in the Unplugged session she co-chaired with José Montes, MD. She discusses some of the latest tightening devices for the face, neck, and body, including EmFace, Zaffiro, and Sofwave. Plus, she reviews topics presented by colleagues throughout tDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)Estrogen and Skin: What Can We Do
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/estrogen-and-skin-what-can-we-do/20123/There’s accumulated evidence that depletion of estrogen with age contributes to the visible signs of skin aging. But dermatologists haven’t had many treatment options—until now. Joel L. Cohen, MD addresses the latest developments in care for estrogen deficient skin.Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.Clinical Conversations: MOA of JAK Inhibitors in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-moa-of-jak-inhibitors-in-dermatology/20096/JAK inhibitors have a range of potential applications in clinical dermatology. In the first video of this series, Brad Glick, DO and Raj Chovatiya, MD explain the mechanism of action of JAK inhibitors and explain how they may be used topically or systemically to treat skin diseases like atopic dermaChallenging Cases
https://practicaldermatology.com/conferences/maui-derm-2022/challenging-cases/20054/Seemal R. Desai, MD was part of the Challenging Cases session on everything from new infectious diseases to challenging surgical and aesthetic complications. He says dermatologists play an important role in saving and transforming patients' lives.Cosmetic Surgery Forum: 2021 Recap
https://practicaldermatology.com/topics/skin-cancer-photoprotection/cosmetic-surgery-forum-2021-recap/20032/Cosmetic Surgery Forum founder and director Joel Schlessinger, MD offers an overview of the 2021 conference in Nashville.DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesScientifically Speaking: When Accidents Happen in the Surgical/Aesthetic Clinic
https://practicaldermatology.com/topics/practice-management/scientifically-speaking-when-accidents-happen-in-the-surgicalaesthetic-clinic/19906/Surgical and laser procedures bring risks for infections, ocular injury, scarring, and more. In the second of a 2-part series, experts discuss best practices for managing adverse reactions with an emphasis on early intervention. Host Joel L. Cohen, MD leads the conversation with Mathew Avram, MD, JD